secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-05-21T23:59:59+00:00
Accession:  0001641172-25-011873
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata initiates XYNGARI drug product manufacturing; Phase 3 STAR-2 trial expected Q4 2025
--------------------------------------------------------------------------------

- Manufacturing for XYNGARI drug product initiated for Phase 3 STAR-2 trial; trial start expected Q4 2025.
- Topline data from STAR-2 expected H1 2027; patients can rollover into 9-month extension study.
- NDA filing for XYNGARI anticipated in H1 2028 after extension study completion by end of Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/0001641172-25-011873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225011873/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-011873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer